Academic Journals Database
Disseminating quality controlled scientific knowledge

Pharmacology and clinical potential of oblimersen sodium in the treatment of chronic lymphocytic leukemia

Author(s): Borthakur G | O'Brien S

Journal: Blood and Lymphatic Cancer : Targets and Therapy
ISSN 1179-9889

Volume: 2012;
Issue: default;
Start page: 137;
Date: 2012;
Original page

Gautam Borthakur, Susan O'BrienDepartment of Leukemia, MD Anderson Cancer Center, Houston, TX, USAAbstract: Targeted inhibition of the Bcl-2 family of antiapoptotic proteins is expected to improve outcomes in chronic lymphocytic leukemia. Antisense oligonucleotides and small molecule inhibitors (BH3 mimetics) are two approaches that have been used to target Bcl-2 proteins. In this review, we summarize the experience with oblimersen sodium, an 18-base oligonucleotide targeting the first six codons of Bcl-2 mRNA, with particular focus on chronic lymphocytic leukemia. Despite evidence of improved outcomes in randomized trials of combination with chemoimmunotherapy, further development of this antisense approach has been slow, likely because of the clinical development of small molecule inhibitors.Keywords: oblimersen, Bcl-2, antisense, chronic lymphocytic leukemia
RPA Switzerland

RPA Switzerland

Robotic process automation


Tango Jona
Tangokurs Rapperswil-Jona